Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06009874
Recruiting Not applicable

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

NCT06009874 · tracked via the Priya Life Science Egypt tracker
Sponsor
Mohammad Hussien Tantawy Soliman
Phase
Not applicable
Started
2023-12-20
Last updated
2026-10-14

Condition(s) studied

Myocardial Infarction

Investigational drug(s) / intervention(s)

Dapagliflozin 10mg Tab →Placebo

Dapagliflozin 10mg Tab: patients will be treated with DAPA 10 mg once daily for three months

Placebo: patients will be treated with a placebo tab once daily for three months

Study summary

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients with ST-elevation myocardial infarction (STEMI). 2. STEMI was defined according to the Fourth Universal Definition of AMI. 3. 18 - 80 years of age. 4. Diabetics or non-diabetics. 5. eGFR \> 45 ml/min/1.73m2. 6. Blood pressure before first drug dosing \>110/70 mmHg. Exclusion Criteria: 1. Cardiogenic shock. 2. Hypoglycemia. 3. History of diabetic ketoacidosis. 4. Genital and urinary infections. 5. History of AMI. 6. Stent thrombosis. 7. Previous coronary artery bypass surgery. 8. Severe hepatic insufficiency. 9. Advanced cancer patients. 10. Blood pH \< 7.32. 11. Known allergy to SGLT-2 inhibitors. 12. Hemodynamic instability. 13. Females of childbearing potential without adequate contraceptive methods. 14. Patients currently on or have received any SGLT-2 inhibitors.

Primary outcome measure(s)

  • difference in infarct size — 3 months
    infarct size measurement (percentage) for both groups
  • difference in NT-proBNP level — 3 months
    NT-proBNP level (pg/ml) for both groups

Trial sites (1)

FacilityCityRegionStatus
Mohammad Soliman Shibīn al Kawm Menofia Recruiting

Other trials for the same condition

Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI Active, not recruiting
Effectiveness of Digital Cardiac Rehabilitation on Functional Capacity in Patients With Myocardial Infarction Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06009874 on ClinicalTrials.gov ↗ ← All trials in Egypt